CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 338,700 shares, a growth of 88.1% from the March 15th total of 180,100 shares. Approximately 11.6% of the shares of the company are sold short. Based on an average trading volume of 634,900 shares, the short-interest ratio is currently 0.5 days.

CNS Pharmaceuticals Price Performance

CNS Pharmaceuticals stock traded down $0.14 during mid-day trading on Wednesday, reaching $0.82. The company had a trading volume of 312,001 shares, compared to its average volume of 287,361. The stock’s 50-day simple moving average is $2.79 and its 200-day simple moving average is $4.73. CNS Pharmaceuticals has a 1 year low of $0.82 and a 1 year high of $800.00. The company has a market capitalization of $2.41 million, a P/E ratio of -0.01 and a beta of 2.72.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Alliance Global Partners raised shares of CNS Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 24th. Maxim Group reissued a “hold” rating on shares of CNS Pharmaceuticals in a report on Tuesday, March 25th.

Hedge Funds Weigh In On CNS Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Wealthfront Advisers LLC acquired a new stake in CNS Pharmaceuticals in the fourth quarter valued at $26,000. Geode Capital Management LLC increased its holdings in CNS Pharmaceuticals by 90.5% during the 4th quarter. Geode Capital Management LLC now owns 387,064 shares of the company’s stock valued at $47,000 after acquiring an additional 183,884 shares in the last quarter. XTX Topco Ltd acquired a new position in CNS Pharmaceuticals during the fourth quarter worth about $36,000. Integrated Wealth Concepts LLC acquired a new stake in shares of CNS Pharmaceuticals in the fourth quarter valued at approximately $30,000. Finally, Jane Street Group LLC increased its stake in shares of CNS Pharmaceuticals by 1,712.3% during the 4th quarter. Jane Street Group LLC now owns 419,737 shares of the company’s stock worth $51,000 after purchasing an additional 396,577 shares in the last quarter. 14.02% of the stock is owned by hedge funds and other institutional investors.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.